BIOGEN INC. Proceeds from Divestiture of Businesses
BIOGEN INC. (BIIB) reported Proceeds from Divestiture of Businesses of $0 for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-10-25.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromDivestitureOfBusinesses · last filed 2022-10-25
- BIOGEN INC. proceeds from divestiture of businesses for the quarter ending 2022-09-30 was $0.00.
- BIOGEN INC. proceeds from divestiture of businesses for the quarter ending 2022-06-30 was $0.00.
- BIOGEN INC. proceeds from divestiture of businesses for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- BIOGEN INC. proceeds from divestiture of businesses for the quarter ending 2021-09-30 was $0.00.
| Period end | Proceeds from Divestiture of Businesses 3 month | Proceeds from Divestiture of Businesses 6 month | Proceeds from Divestiture of Businesses 9 month |
|---|---|---|---|
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-25 | $0.00 derived: sum of 2 quarters · filed 2022-10-25 | $0.00 10-Q · filed 2022-10-25 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-20 | $0.00 10-Q · filed 2022-07-20 | |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-03 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-25 | $0.00 derived: sum of 2 quarters · filed 2022-10-25 | $28.10M 10-Q · filed 2022-10-25 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-20 | $28.10M 10-Q · filed 2022-07-20 | |
| 2021-03-31 | $28.10M 10-Q · filed 2022-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |